ライフサイエンスコーパス: there remain

1 However, there remain a large number of TFs ( approximately 800)

2 However, there remain a limited number of mouse models of cleft l

3 ing predators, and advertising toxicity [1], there remain a multitude of species that display conspic

4 However, there remain a number of diseases for which there are no

5 However, there remain a number of technical challenges to be solv

6 ienced rapid growth over the last few years, there remain a relatively small number of material class

7 ssfully in murine embryonic stem (ES) cells, there remain a set of nearly two thousand genes that hav

8 However, there remain a subset of patients who have continued sev

9 ions used automatic tube current modulation, there remained a large variation of practice, on the ord

10 tatin therapy candidates at 55 years of age, there remained a significant association between cumulat

11 gitation from baseline to post intervention, there remained a statistically significant difference (p

12 However, there remained a wide variation in practice, sometimes b

13 I propose that there remains a central role for the item (or its equiva

14 However, there remains a challenge to design a practical path fro

15 ulates avoid energy infrastructure; however, there remains a common perception that ungulates habitua

16 cultural production throughout the world, so there remains a compelling need to develop new vector an

17 However, there remains a considerable gap between genotype-to-gen

18 loss of VHL is an almost ubiquitous finding, there remains a conspicuous lack of targetable genetic d

19 ng to re-open and relax stay-at-home orders, there remains a continued need for careful surgical sche

20 Thus, there remains a critical need for HH inhibitors with dif

21 There remains a critical need for randomized clinical tr

22 quantification have decreased considerably, there remains a critical need for researchers to optimiz

23 However, there remains a critical need to define the precise temp

24 ecies and environmental conditions; as such, there remains a critical need to focus research efforts

25 As such, there remains a critical need to identify key regulators

26 However, there remains a dearth of evidence guiding treatment in

27 rovements in the microbial diagnostic field, there remains a disconnect between clinicians and some p

28 have been developed to improve performance, there remains a gap between promising laboratory results

29 potential of new drugs and small molecules, there remains a gap in the ability to efficiently delive

30 However, there remains a general gap in understanding among clini

31 Consequently, there remains a great need for reliable serum markers fo

32 edict the anti-cancer therapeutic responses, there remains a great need to develop highly accurate pr

33 s event could have been anticipated and that there remains a high chance of exceeding observed record

34 anticipated, and that in the current climate there remains a high chance of exceeding the observed re

35 although even with antimicrobial treatment, there remains a high risk of pregnancy loss.

36 gnosis and high relapse after treatment, but there remains a lack of biomarkers and effective targete

37 There remains a lack of clarity regarding the influence

38 tabolism are known to be implicated in MNDs, there remains a lack of clarity regarding the key functi

39 However, there remains a lack of consensus on the optimal route a

40 y can be enhanced by proteomic evidence, but there remains a lack of consensus on the performance of

41 However, there remains a lack of detailed, systematic studies ass

42 However, there remains a lack of direct structural evidence to su

43 Nevertheless, there remains a lack of effective, targetted diagnostic

44 There remains a lack of evidence concerning both pharmac

45 psoriasis patients using an IL-17 inhibitor, there remains a lack of evidence to suggest a causal rel

46 However, there remains a lack of good evidence for the efficacy o

47 ew vessels from the preexisting vasculature, there remains a lack of insight of the nuclear transcrip

48 However, there remains a lack of practical methods to detect and

49 However, there remains a lack of statistically sound frameworks t

50 e of death in pediatric neuroblastoma, where there remains a lack of therapies to target this stage o

51 However, there remains a lack of understanding regarding ripple d

52 There remains a large discrepancy between the known gene

53 variety of computational genomics problems, there remains a large gap in our understanding of how th

54 factors are well established as carcinogens, there remains a large knowledge gap of others owing to t

55 There remains a limited role for angioplasty because thi

56 There remains a major unmet need for successful manageme

57 There remains a need for a broadly applicable, hernia-sp

58 Despite advances, there remains a need for a method that combines the simp

59 There remains a need for additional high-quality longitu

60 e recent improvements in sequencing methods, there remains a need for assays that provide high sequen

61 ing cause of death in developed nations, and there remains a need for cardiac therapeutic systems tha

62 There remains a need for consensus on practical aspects

63 ols are inconvenient to use in practice, and there remains a need for easy-to-use cross-platform tool

64 ment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progre

65 However, there remains a need for further improvements in sensiti

66 There remains a need for heightened levels of concern re

67 ed the effects of key individual parameters, there remains a need for multi-factor experiments (e.g.,

68 n space, has significant clinical value, but there remains a need for neuroimaging techniques to impr

69 However, there remains a need for standardization of preanalytica

70 There remains a need for such compounds with the balance

71 ed structure in data to generate hypotheses, there remains a need for testing hypotheses and interpre

72 However, there remains a need for the development of analytical m

73 toward the development of new IR probes, but there remains a need for those that can extend the exper

74 he emergence of site-specific endonucleases, there remains a need for tools capable of specifically d

75 ocesses that are enriched in the genes sets, there remains a need for tools that identify enrichment

76 There remains a need in clinics and research to have sim

77 costs and eliminate complicated procedures, there remains a need to address probe costs and generali

78 There remains a need to analyze data across institutions

79 However, there remains a need to anticipate supply given the rapi

80 Yet, there remains a need to assess the AHQ's clinical applic

81 aneous mastocytosis (CM) have been proposed, there remains a need to better define subforms of cutane

82 key contributors to metastatic disease, and there remains a need to better understand and target the

83 Notwithstanding the foregoing, there remains a need to develop a conceptual framework t

84 There remains a need to develop noninvasive predictors o

85 er still carries a poor prognosis, and thus, there remains a need to elucidate the molecular mechanis

86 and mortality associated with this disease, there remains a need to elucidate the molecular mechanis

87 Nevertheless, there remains a need to focus on the "last mile" in remo

88 There remains a need to identify new sensitive diagnosti

89 There remains a need to identify novel pro-resolution dr

90 rapeutic potential in severe infections, but there remains a need to substantiate clinical benefit.

91 n tissue development and cell proliferation, there remains a paucity of approaches to investigate the

92 Despite routine clinical use, there remains a paucity of data on their effectiveness a

93 have substantially advanced in recent years, there remains a paucity of evidence for treatment.

94 However there remains a paucity of information about overall cap

95 noid system has immunomodulatory properties, there remains a paucity of information on the effects of

96 There remains a paucity of information on the status of

97 There remains a paucity of real-world observational evid

98 Despite these advances, there remains a paucity of robust and accepted biomarker

99 e being a significant healthcare cost burden there remains a paucity of studies in the literature eva

100 smell can accomplish astonishing feats, yet there remains a prevailing belief that olfactory languag

101 ated control of clade B HIV-1 infection, yet there remains a relative paucity of data regarding the r

102 However, there remains a scarcity of evidence about the performan

103 Despite this, there remains a scarcity of software packages that provi

104 crease in women entering surgical residency, there remains a sex disparity in surgical leadership.

105 However, there remains a shortage of specific databases that can

106 gand interactions to identify new compounds, there remains a shortage of specific databases with prec

107 ial meningitis in children has decreased but there remains a significant burden of disease in adults,

108 However, there remains a significant disconnect between theory an

109 of patients on the transplant waiting list, there remains a significant gap between the need for tra

110 aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identif

111 However, there remains a significant lack of generators capable o

112 There remains a significant need for development of effe

113 As a result, outcomes are generally poor and there remains a significant unmet need for novel therape

114 f high-quality evidence and robust guidance, there remains a significant variation in some elements o

115 several potent agonists have been described, there remains a strong need for suitable tracers to inte

116 However, there remains a substantial challenge to produce long-st

117 Despite these advances, there remains a substantial need for more high-quality e

118 There remains a substantial number of MoAs that were har

119 There remains a substantial unmet medical need in hemoph

120 Yet, there remains a surprising lack of tools for GSE testing

121 able progress in DNA sequencing technologies there remains a trade-off between short-read platforms,

122 There remain also needs to understand broader categories

123 us studies in this area in recent years, but there remains an imperative to demonstrate that the curr

124 As such, there remains an important clinical need to develop ways

125 There remains an important need for prophylactic anti-Eb

126 d differences in case mix between operators, there remains an inverse relationship between PCI operat

127 Furthermore, there remains an unmet demand for an efficient survey of

128 There remains an unmet dermatological need for innovativ

129 Therefore, there remains an unmet need for a novel therapeutic appr

130 ious diseases caused by pathogenic bacteria, there remains an unmet need for diagnostic tools that ca

131 Thus, there remains an unmet need for early diagnostic and pro

132 global threat from drug-resistant superbugs, there remains an unmet need for simple and accessible di

133 notechnological solutions to biosensing, yet there remains an unmet need in the development of biosen

134 However, there remains an unmet need to turn molecular self-assem

135 Hence, there remains an urgent need for antidiabetic therapeuti

136 ts in column technology and instrumentation, there remains an urgent need for creating innovative app

137 ite significant advancements over the years, there remains an urgent need for low cost diagnostic app

138 There remains an urgent need for rapid diagnostic method

139 However, there remains an urgent need to develop new vaccines for

140 of AILDs and liver transplantation evolves, there remain areas of unmet needs.

141 therapy for insulin-dependent diabetes, but there remain challenges towards achieving this goal(1-6)

142 talyzed C(sp(3))-C cross-coupling reactions, there remain challenging bond formations.

143 However, there remains concern about their efficacy and safety.

144 There remains concern regarding the occurrence of noncom

145 type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity.

146 transcatheter aortic valve replacement, yet there remain conflicting reports about the effect of sex

147 There remain conflicts and uncertainties in specific cas

148 sed by critical care organizations; however, there remains confusion about what shared decision makin

149 n and the development of cold hardiness, but there remain considerable gaps deserving further researc

150 ite this significant pharmaceutical success, there remain considerable limitations to broad medicinal

151 There remains considerable debate over the active form o

152 echanisms of signal production and response, there remains considerable debate over the functional ro

153 ommon task in biological investigations, yet there remains considerable room for improvement in align

154 Given these findings, there remains considerable room for improvement, especia

155 forests respond with increased productivity, there remains considerable uncertainty as to how the lon

156 There remains considerable uncertainty in how anthropoge

157 rent histopathological classification system there remains considerable uncertainty in predicting tum

158 a leading cause of worldwide disability but there remains considerable uncertainty regarding its neu

159 There remains considerable variability in the distributi

160 d the debate over how many tree species grow there remains contentious.

161 Despite their success, there remain critical barriers to the more widespread us

162 This notwithstanding, there remain critical development issues and knowledge g

163 dergoing percutaneous coronary intervention, there remains debate about differences in efficacy and t

164 entary imaging is occasionally required when there remains diagnostic uncertainty following transesop

165 lowing discussion among the consensus group, there remained disagreement in 10 cases (kappa = 0.91; 9

166 axSpA disease concept is universally agreed, there remains disagreement about operationalizing aspect

167 Hypertonic saline is used predominantly, yet there remains disagreement about whether hypertonic sali

168 But there remain enormous uncertainties about the atomistic

169 AV pandemics can be traced to avian origins, there remains ever-present concern over emerging IAVs wi

170 e for the preparation of aromatic compounds, there remain few methods that allow their conversion int

171 However, there remain few operationally simple methods for their

172 nance of contemporary patterns of diversity, there remain few standardized biogeographic comparisons

173 idelines are appropriate for cardiology, but there remain fundamental differences between trauma and

174 For example, there remain fundamental open questions on the phase dia

175 There remain gaps in knowledge concerning how vascular m

176 However, there remain gaps in our knowledge, primarily regarding

177 Although there remain gaps in our understanding of how the interc

178 iterative process of model development, and there remains great opportunity for advancing our unders

179 However, there remains great variability in the current clinical

180 There remain however several points of contention.

181 There remain, however, many challenges related to the ac

182 There remains, however, a need for methods to propel and

183 There remains, however, a need to examine eDNA persisten

184 There remains, however, a pressing need to elucidate str

185 There remains, however, an unexplained link between hypo

186 There remains, however, the need for an efficient APRM c

187 f the breadth of this public health problem, there remain important gaps in scientific knowledge rega

188 Mortality rates continue to be high and there remain important opportunities for further improve

189 ly on inefficient phenotypic approaches, and there remains incomplete understanding of AMR mechanisms

190 There remains insufficient evidence to provide guidance

191 There remain issues such as how to cluster molecular seq

192 le nucleotide polymorphisms (SNPs); however, there remains large room for improvements in running tim

193 ave increased diversity in food choices, but there remains limited evidence linking these innovations

194 There remains limited insight into the pathophysiology a

195 However, despite its clinical importance, there remains limited understanding of mechanisms underl

196 There remains limited understanding of the complex and d

197 of charged energetic particles, for decades there remained little direct observational evidence that

198 d States have increased in recent years, yet there remains little attention on liposuction, or debulk

199 lume fluid administration for major surgery, there remains little consensus on optimal strategies, du

200 However, despite attention in model systems, there remains little data on how recombination rate vari

201 T1) can contribute to neuronal excitability, there remains little information on the physiological ro

202 There remains little national data evaluating the associ

203 There remain major challenges to implementing pulse oxim

204 the Expanded Program on Immunization (EPI), there remain major challenges to more effective vaccinat

205 and powerful analysis methods are available, there remain many challenges to reliable tree building.

206 e databases, and better data analysis tools, there remain many challenges to the routine use and impl

207 There remain many more genetics variants with small effe

208 However, despite their apparent success, there remain many open questions about their intrinsic p

209 t has been evaluated in clinical trials, and there remain many opportunities to further investigate k

210 merous cellular targets have been described, there remain many questions about the mechanism of NSP1

211 ge and advances in prevention and treatment, there remain many questions about this decline.

212 Despite this, there remain many regions for which no atmospheric monit

213 ector secretion and host defence mechanisms, there remain many unanswered questions about fundamental

214 ion referred to as "reverse seroconversion." There remain many uncertain areas that warrant further s

215 There remain many uncertainties regarding this pathway.

216 There remain metabolic deficits following restoration of

217 blast cells is a well-recognized phenomenon, there remains minimal data on differences in MDR activit

218 chanisms on simplified membrane systems, but there remain missing connections between the complex env

219 nergy nuclear reactions, and we contend that there remains much interesting science to be done in thi

220 There remains much scientific, clinical, and ethical con

221 f current management of ischemic stroke, but there remains much to be learned about mechanisms of neu

222 g the surfaces of these frameworks, although there remains much to be learned about the origins of th

223 ifferences between broad tissue types exist, there remains much to be understood about the splicing f

224 ature, but with nearly seventy-five species, there remains much to explore in this genus.

225 ry of 2-phosphaethynolate is burgeoning, but there remains much to learn about this ligand, for examp

226 Currently, there remains much unknown about CRF-dependent regulatio

227 There remain no uniform classification criteria that are

228 Overall there remain no validated biomarkers in the youth popula

229 n characterizing and modeling this response, there remains no consensus as to the mechanism that driv

230 munologic injury to the renal allograft, yet there remains no consensus on how best to monitor drug t

231 herapies have improved patient survival, but there remains no definitive cure.

232 There remains no direct evidence on effects of prenatal

233 eserved ejection fraction (HFpEF) in humans, there remains no evidence-based therapies for HFpEF.

234 establishes a persistent infection for which there remains no feasible cure.

235 leading cause of infant hospitalization and there remains no pediatric vaccine.

236 pite intense research for the past 25 years, there remains no safe and effective vaccine available.

237 ecular resistance mechanisms is limited, and there remains no standardized DST method.

238 hat target proteins for therapeutic benefit, there remains no substitute for the natural properties o

239 ver, despite importance for clinical trials, there remains no transcriptomic biomarker for FSHD progr

240 with high rejection rates in MPS1 children, there remains no treatment to prevent blindness or resto

241 vaccines in preventing infectious diseases, there remain numerous globally devastating diseases with

242 ed organic matter ((3)CDOM*) reactivity, but there remain open questions about the reaction kinetics

243 There remain open questions in the signaling networks, t

244 espite its widespread use over four decades, there remain open questions regarding its fundamental li

245 There remain opportunities for improvement in medication

246 While early results remain encouraging there remain opportunities for improvement.

247 these early years following introduction, so there remains potential for further disease reductions.

248 not yet achieved any commercial success, as there remain problems with capacity fade after extended

249 ictions and total allowable catch (TAC), but there remain problems with compliance and high levels of

250 Nonetheless, there remain psychiatric domains unique to humans.

251 f recurrent cardiovascular events after ACS, there remain questions about how aggressively to reduce

252 Despite this, there remain remarkably few studies investigating the us

253 Nonetheless, there remains reticence among transplant surgeons to tra

254 spectra obtained from cross-linked peptides, there remains room for improvement.

255 is frequently associated with cataract, but there remains scant information about DS cataract morpho

256 andidates is fully assessed by these trials, there remains scope for the discovery of inhibitors from

257 tant viruses of grapevine but, despite this, there remain several gaps in our understanding of its bi

258 There remain several great and lingering challenges to b

259 h in HCV therapeutic development approaches, there remain several key obstacles to the broad implemen

260 However, there remain several open challenges in designing adapti

261 There remain several outstanding questions in spatial ec

262 However, there remain significant challenges in the synthesis of

263 been made on materials performance; however, there remain significant concerns about operational and

264 h hiring additional staff may be beneficial, there remain significant financial limitations for many

265 Despite these efforts, there remain significant gaps in our knowledge concernin

266 SUMMARY BACKGROUND DATA: There remain significant gaps in our understanding of ac

267 rt of efforts to eliminate malaria, however, there remain significant gaps in our understanding of mo

268 However, there remain significant knowledge gaps about the variat

269 There remain significant regional disparities in the man

270 ing advances in the field of nanotechnology, there remain significant research gaps and the opportuni

271 tment for biologically plausible covariates, there remained significant associations of total 25-hydr

272 Nevertheless, there remained significant disagreements, centered large

273 AN practice parameters was readily apparent, there remained significant variability across all 5 cate

274 ers provide maps of the "spatial gradients," there remains significant confusion because of the lack

275 nder local or general anaesthesia exist, and there remains significant debate within the field regard

276 in the pathology of CNS disorders, however, there remains significant uncertainty about the neuropro

277 Despite this substantial progress, there remains significant work to be accomplished.

278 sets of identified palmitoyl-proteins and so there remains some uncertainty over what constitutes the

279 Owing to conflicting data, there remains some uncertainty regarding the most benefi

280 g the obligate liver stage of infection, yet there remains sparse knowledge of specific host regulato

281 GPCRs) can treat multiple diseases; however, there remains substantial interest in the development of

282 roved treatment such as methadone, for which there remains the best evidence of efficacy, may be the

283 However, there remains the need for alternative insecticidal acti

284 There remains the need, however, for a soluble, versatil

285 There remain thousands of potentially important genomic

286 However, there remain unanswered questions about the mechanism of

287 There remain unanswered questions surrounding surgical c

288 etic variants associated with schizophrenia, there remains uncertainty about the causal genes involve

289 scribed sex differences in asthma incidence, there remains uncertainty about the role of female sex h

290 There remains uncertainty about the true specificity of

291 However, there remains uncertainty about whether these thin sheat

292 recedented opportunities for drug discovery, there remains uncertainty concerning the path to the cli

293 Moreover, there remains uncertainty of which thresholds are the mo

294 erstanding of the molecular characteristics, there remains uncertainty regarding epidemiologic trends

295 For displaced femoral neck fractures, there remains uncertainty regarding the effect of a tota

296 Furthermore, there remains uncertainty regarding the relative importa

297 limb loss, morbidity and mortality; however, there remains unmet therapeutic needs for arterial revas

298 ged 9 years and older has been licensed, but there remains urgent medical need for a vaccine that is

299 ong the countries where these are available, there remains variability.

300 ss to adequate care than that at present, as there remains variation in survival between European reg